**Tables and Figures**

**Table 1. Recommended annual frequency of eGFR testing in people with CKD (number of tests)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | **ACR categories** (mg/mmol) | | |
| **A1**  (<3) | **A2**  (3-30) | **A3**  (>30) |
| **eGFR categories** (ml/min/1.73m2) | **G1** (≥90) | 1 if CKD | 1 | 2 |
| **G2** (60-89) | 1 if CKD | 1 | 2 |
| **G3a** (45-59) | 1 | 2 | 3 |
| **G3b** (30-44) | 2 | 3 | 3 |
| **G4** (15-29) | 3 | 3 | 4+ |
| **G5** (<15) | 4+ | 4+ | 4+ |


**Table footnotes:** Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, very high risk. Reproduced with permission from: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.

**Table 2. KDIGO recommended BP targets for people with CKD**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | | **ACR categories** (mg/mmol) | | |
| **A1**  (<3) | **A2**  (3-30) | **A3**  (>30) |
| **Diabetes status** | **Diabetes** | Systolic | ≤140 | ≤130 | ≤130 |
| Diastolic | ≤90 | ≤80 | ≤80 |
| **No diabetes** | Systolic | ≤140 | ≤130 | ≤130 |
| Diastolic | ≤90 | ≤80 | ≤80 |


**Figures**

**Figure 1.** **Prognosis of CKD by GFR and albuminuria category**

****

**Figure footnotes:** Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, very high risk. Figure reproduced with permission from: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.

**Figure 2. Clinical decision pathway in CKD diagnosis in relation to eGFR**.

****

**Figure footnotes:** Blue boxes represent clinical actions, grey boxes represent findings.